Studies have shown that S100A8- and S100A9-mediated inflammation can alter hepatic lipid metabolism by increasing lipogenesis and decreasing cholesterol efflux, contributing to dyslipidemia (45, 46). Here, S100A9 is linked to metabolic syndrome.